Botulinum toxin type A alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2/MyD88 and SNAP23

BACKGROUND: Botulinum toxin type A (BTX-A) was considered to be a new potential drug for neuropathic pain (NP) treatment. RESULTS: In vivo, BTX-A attenuated chronic compression injury (CCI)-induced pain in rats, and reduced production of pro-inflammatory factors. The inhibition of BTX-A to expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuan, Tian, Sheng, Wang, Hansen, Liu, Pan, Zheng, Heqing, Wu, Lanxiang, Liu, Qian, Wu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724852/
https://www.ncbi.nlm.nih.gov/pubmed/33298171
http://dx.doi.org/10.1186/s13578-020-00501-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724852/
https://www.ncbi.nlm.nih.gov/pubmed/33298171
http://dx.doi.org/10.1186/s13578-020-00501-4

Ejemplares similares